Brandi Klingerman | August 13, 2016
In recent years researchers have begun to understand that the development of colon cancer, which is the second most common cancer in the United States, can impact the genome and cause protein changes within cancer cells.
This knowledge has brought new medications and targeted therapies to the marketplace and now a Notre Dame researcher is evaluating the effectiveness of these treatments.
From her laboratory within Notre Dame’s newly opened McCourtney Hall, a 220,000 square foot building dedicated to research in the molecular sciences and engineering,Amanda Hummon, Huisking Foundation, Inc. Associate Professor of Chemistry and Biochemistry and affiliate of the Harper Cancer Research Institute (HCRI) and Advanced Diagnostics and Therapeutics initiative, is conducting fundamental research on the differences between cancer on the right versus the left side of the colon to evaluate cancer medications.